猕猴发育过程中肠肝组织血管活性肠肽及其受体的变化

本文旨在探讨猕猴发育过程中血管活性肠肽(vasoactive intestinal polypeptide,VIP)及其受体在肠肝组织的变化。通过手术途径获得胚胎6月、新生2 d、新生45 d和成年猕猴的回肠、肝脏、门静脉和外周血等标本,应用放射免疫分析法测定各标本中的VIP含量;通过免疫组化方法观察VIP在肠、肝组织内的分布;利用原位杂交法检测VIP受体1(VIP receptor 1,VIPR1)的表达。结果显示:(1)胚胎6月的猕猴小肠VIP含量为(20．7±14．3)ng／mg蛋白;小肠绒毛根部及黏膜下层可见少量的VIP阳性染色颗粒;在发育过程中,小肠VIP含量逐渐增加,成年期时达(514．8±49．2)ng／mg蛋白,较胚胎6月显著增加(P<0．01)。(2)成年猕猴小肠VIP主要分布于绒毛隐窝部、黏膜下层神经及环、纵行肌间神经丛及环行肌,在发育过程中相应部位的VIPR1表达逐渐上调。(3)肝脏在发育过程中VIP及VIPR1含量逐渐降低。(4)发育的各个时期,小肠组织的VIP含量均明显高于肝脏组织,门静脉VIP水平也始终高于外周血。结果提示,小肠绒毛隐窝部、黏膜下层神经及环、纵行肌间神经内VIP及VIPR1含量足在出生以后才迅速增加的;不论是在胚胎还是成年期,VIP均不在肝中代谢和分解,VIPR1仅见于胚胎肝脏血管。     

发育过程中肝脏血管活性肠肽及其受体量的变化

已有的研究观察到,胚胎肝脏中血管活性肠肽(vasoactiveintestinalpolypeptide,VIP)及其受体(vasoactiveintesti-nalpolypeptidereceptor,VIPR)与造血干细胞生长和肝脏发育有关。本研究旨在了解发育过程中肝VIP及VIPR量的动态变化。采用放射免疫分析法、生物分子相互作用系统和RT-PCR等技术检测了各发育阶段大鼠肝组织VIP浓度、VIP受体结合量及VIP受体表达亚型,实验观察到胎鼠和新生鼠肝脏VIP浓度显著低于未成年鼠及成年鼠肝脏VIP浓度(P<0.05)。发育尚未成熟时(胎鼠、新生鼠、未成年鼠),肝VIPR表达均明显高于成年鼠(P<0.05),表明大鼠在发育过程中肝脏VIP与VIP受体量呈相反的变化趋势。大鼠发育各时期,肝脏均表达VIPR-1。这些结果部分解释了肝脏发育、肝脏造血转移等重要生理现象。     

鳜两种生长抑素受体cDNA全长克隆与组织表达

利用cDNA末端快速扩增(RACE)技术克隆了鳜(Siniperca chuatsi)脑中2种生长抑素受体(somatostatin receptor,SSTR2和SSTR3)cDNA全长序列。结果显示,鳜SSTR2 cDNA全长1 820 bp,含开放阅读框1 146 bp,编码382个氨基酸;SSTR3 cDNA全长1 874 bp,含开放阅读框1 458 bp,编码486个氨基酸。SSTR均由5个结构区域组成:N端、7个转膜区(TMD)、3个细胞外袢(ECLs)、4个细胞内袢(ICLs)和C末端。NJ系统进化树分析显示,鳜SSTR2和SSTR3分别形成相对独立的分支,两者间的氨基酸序列相似度为51.2%,表明它们是由不同基因编码而成。利用实时荧光定量RT-PCR技术检测了鳜SSTR2和SSTR3 mRNA的组织表达特征,它们均在多种组织中广泛表达,SSTR2 mRNA在肝中表达量最高,SSTR3 mRNA在胃中表达量最高。SSTR2、SSTR3表达差异反映它们可能参与不同生理调控作用。     

生长抑素受体2的小鼠时空组织表达谱

生长抑素(somatostatin, SST)作为一种抑制性多肽激素,在多种生物过程中发挥重要的功能。生长抑素受体2 (somatostatin receptor 2, SSTR2)作为生长抑素表达最广泛的受体在多种组织中表达,但其表达的具体细胞类型尚不清楚。本研究在小鼠不同发育阶段的多种组织中鉴定了SSTR2蛋白表达的细胞类型。通过多色免疫荧光在小鼠胚胎期15.5 d、出生后1 d、7 d、15 d、3个月和6个月的脑、骨、肺、肠道、皮肤、胃、脾和肾等组织中检测了Sstr2基因的表达。结果发现Sstr2在不同发育阶段的多种组织的特定细胞类型中表达,包括脑神经元和星形胶质细胞,骨的间充质基质细胞、造血细胞和B细胞,肺的巨噬细胞、Ⅱ型肺泡上皮细胞和气道纤毛细胞,肠道的上皮细胞和神经元,皮肤的毛囊细胞,胃体的上皮细胞,脾的造血干细胞、造血祖细胞和神经纤维,肾的肾小管上皮细胞等。本研究确定了小鼠多组织不同发育阶段Sstr2表达的细胞类型,为生长抑素与生长抑素受体2的生理功能研究提供了新的线索。     

对淤血再灌注肠神经组织损伤机制的探讨

目的:建立大鼠肠淤血再灌注动物模型,探讨淤血再灌注肠神经组织损伤的机制,为临床相关疾病的诊断、治疗提供理论依据.方法:成年Wistar大鼠60只,雌雄不限,随机分为正常组、对照组和实验组,每组20只.实验组采用阻断门静脉1h后开放的方法建立大鼠小肠淤血再灌注模型,对照组只进行同样腹部手术操作但不夹闭门静脉,正常组不手术.6小时后取各组下腔静脉血,测定血清中超氧化物歧化酶(SOD)活性和丙二醛(MDA)的含量,然后处死动物,取距回盲部15厘米处肠管1厘米,采用伊红-苏木素(HE)染色观察肠粘膜组织形态学变化;用免疫组织化学方法观察正常组、对照组和实验组小肠壁肠神经组织中微管相关蛋白2(MAP-2)的表达情况.结果:HE染色可见,正常组、对照组为正常肠道管壁结构,实验组肠壁各层有比较明显的淤血、出血,小肠绒毛固有层水肿,黏膜上皮有脱落、坏死;实验组MAP-2的表达明显低于正常组及对照组(P＜0.05);与正常组及对照组相比较,实验组SOD活性明显降低(P＜0.05),MDA的含量则明显升高(P＜0.05).结论:肠淤血再灌注可能导致肠道神经元数量减少,其机制可能与肠淤血再灌注造成的自由基损伤和脂质过氧化有关.     

不同月龄大鼠空肠粘膜上皮细胞的形态、增殖及凋亡

为研究雄性大鼠空肠在发生、发育和衰老过程中上皮细胞增殖与凋亡形态学的变化,本实验采用增殖细胞核抗原(PCNA)免疫细胞化学染色、原位末端标记(TUNEL)法检测了不同生长发育阶段SD大鼠空肠绒毛粘膜上皮及小肠腺上皮的细胞增殖、凋亡的变化情况,并统计测量了不同发育阶段大鼠空肠绒毛的高度、肌层厚度及绒毛杯形细胞、肠腺杯形细胞的数量变化。观察到大鼠空肠肠腺隐窝增殖细胞的阳性着色表达从出生后开始增强,到3月龄时达最高峰,12月龄时增殖细胞阳性染色又减弱;凋亡细胞主要分布于固有层,凋亡阳性细胞数在3月龄最多;大鼠空肠绒毛的高度从初生后开始增加,到3月龄达顶峰,而后开始变矮;空肠肌层在3周龄、12月龄较厚;杯形细胞数量于生后3周迅速增长,不同发育阶段的大鼠空肠肠腺隐窝的杯形细胞数量与年龄呈正相关。     

牦牛肠源Lactobacillus acidophilus L3对其小肠黏膜形态结构的影响

为了探讨牦牛肠源嗜酸乳杆菌Lactobacillus acidophilus L3对牦牛小肠肠道黏膜形态结构的影响,将10头健康牦牛(2~2.5岁)随机分为2组,分别为益生菌组和空白对照组,益生菌组在饲料中添加2×109CFU·kg-1L.acidophilus L3,饲喂28 d后取其小肠组织样品,采用组织学和显微测量学方法对益生菌组和空白对照组牦牛小肠绒毛高度、隐窝深度、绒毛高度/隐窝深度比值(V/C),以及回肠黏膜淋巴集结厚度进行测量和统计分析。研究结果显示,益生菌组牦牛十二指肠、空肠、回肠绒毛高度均较空白对照组显著增加,隐窝深度降低,V/C值增加,差异有统计学意义(P<0.05)。通过对回肠淋巴集结的测量发现,益生菌组牦牛回肠淋巴集结的平均厚度均较空白对照组显著增加,差异有统计学意义(P<0.05)。研究结果表明,牦牛肠源L.acidophilus L3可有效改善其肠道黏膜结构,增强肠道黏膜免疫效应部位的免疫功能。     

胰高血糖素样肽-2对小鼠小肠缺血/再灌注损伤的保护作用

目的:观察胰高血糖素样肽-2(GLP-2)对缺血/再灌注损伤小鼠小肠的保护效应.方法:采用肠缺血/再灌注(I/R)模型,将32只小鼠随机分为4组(n=8)假手术(Sham)组、I/R组、I/R GLP-2保护组和I/R 谷氨酰胺(GLN)阳性对照组.光镜观察小肠黏膜形态学改变.检测小肠绒毛高度和隐窝深度;小肠组织二胺氧化酶(DAO)活性;肠系膜淋巴结(MLN)细菌易位率.结果:与假手术组相比,I/R组部分小肠绒毛坏死脱落,绒毛高度下降,隐窝变浅(P＜0 01);小肠组织DAO活性降低(P＜0.01);MLN细菌易位率增加(P＜0.05).与I/R组比,GLP-2组肠绒毛损害明显减轻,DAO活性回升(P＜0.01),细菌易位率回降(P＜0.05).结论:GLP-2对缺血/再灌注损伤小鼠小肠的形态结构及肠屏障功能具有保护作用.     

子宫内膜癌组织中生长抑素受体、VEGF的表达及其与血管形成的关系

目的探讨生长抑素受体（somatostatin receptor,SSTR）、血管内皮生长因子（vascular endothelial growth factor,VEGF）在子宫内膜癌组织中的表达及其与肿瘤血管形成的关系。方法应用免疫组织化学方法检测60例子宫内膜癌组织中SSTR各亚型、VEGF及CD34标记的微血管密度（microvessel denisity,MVD）的表达情况,探讨其与子宫内膜癌临床病理学特征及肿瘤血管形成的关系。结果在60例子宫内膜癌组织中,SSTR各亚型（SSTR1、SSTR2、SSTR3、SSTR4及SSTR5）的阳性表达率分别为70．0％,15．0％。21．7％,23．3％及18．3％;SSTR3、SSTR4在中高分化组表达阳性率明显高于低分化组（P〈0．05）。VEGF的阳性表达率为83．3％,VEGF在低分化组表达阳性率明显高于中高分化组、深肌层浸润组表达阳性率明显高于浅肌层浸润组、FIGO分期≥II期组表达阳性率明显高于I期组（P〈0．05）。子宫内膜癌组MVD（44．85±15．78）明显高于正常子宫内膜组MVD（18．96±4．30）（P〈0．01）。SSTR5的表达与VEGF呈负相关,VEGF阳性表达组子宫内膜癌组织MVD高于VEGF阴性组。结论联合检测SSTR和VEGF对子宫内膜癌预后的评估有一定临床意义。生长抑素类似物（somatostatin analogs,SSTA）可能为子宫内膜癌的诊治提供新的靶点。     

骨髓间充质干细胞动员内源性干细胞修复放射性肠黏膜损伤的实验研究

目的探索骨髓间充质干细胞（MSCs）对放射性肠炎（RE）肠黏膜修复的途径。 方法体外分离、培养大鼠骨髓MSCs。将RE模型的大鼠采用随机数字表法分为治疗组[经尾静脉注射干细胞悬液1 mL（细胞浓度为1×10⁶个/mL）]和对照组（注射等量生理盐水,每日1次,连续3 d）,每组10只。每日观察两组大鼠的活动量、进食和进水量、体质量变化等。1周后处死大鼠获取小肠标本,HE染色观察肠黏膜的修复情况,电镜观察上皮细胞的超微结构,免疫组化染色观察小肠隐窝Bmi-1阳性干细胞增殖情况,采用Image-Pro Plus 6.0软件对Bmi-1阳性细胞数量进行分析。组间差异的比较采用t检验。 结果成功分离得到大鼠骨髓MSCs,流式细胞仪鉴定：CD29、CD90、CD34、CD45阳性细胞比例分别为98.6﹪、99.6﹪、0.56﹪、0.89﹪。与对照组相比,治疗组大鼠移植1周后,体质量增加（190.30 g ± 13.23 g比235.00 g±14.30 g）;大鼠小肠黏膜上皮得到修复,绒毛高度增高（627.50 μm ± 40.55 μm比984.33 μm ± 61.80 μm）;上皮细胞超微结构较完整、清晰,隐窝Bmi-1阳性干细胞增殖数量增多[（60.67±9.63）个/mm²比（87.33 ±5.47）个/mm²],差异具有统计学意义（P < 0.05）。 结论骨髓MSCs能促进RE模型的大鼠肠黏膜的修复,这一作用可能是通过促进小肠隐窝干细胞的增殖发挥。     

Distribution of PACAP (pituitary adenylate cyclase-activating polypeptide)-like and helospectin-like peptides in the teleost gut

Pituitary adenylate cyclase-activating polypeptide (PACAP) and helospectin are two vasoactive intestinal polypeptide (VIP)-related neuropeptides that have recently been demonstrated in the mammalian gut; the aim of this study was to reveal their occurrence and localisation in the gastrointestinal tract, swimbladder, urinary bladder and the vagal innervation of the gut of teleosts, using immunohistochemical methods on whole-mounts and sections of these tissues from the Atlantic cod, Gadus morhua and the rainbow trout, Oncorhynchus mykiss. Both PACAP-like and helospectin-like peptides were present in the gut wall of the two species. Immunoreactive nerve fibres were found in all layers but were most frequent in the myenteric plexus and along the circular muscle fibres. Immunoreactivity was also demonstrated in nerves innervating the swimbladder wall, the urinary bladder and blood vessels to the gut. Immunoreactive nerve cell bodies were found in the myenteric plexus of the gut and in the muscularis mucosae of the swimbladder. In the vagus nerve, non-immunoreactive nerve cells were surrounded by PACAP-immunoreactive fibres. Double staining revealed the coexistence of PACAP-like and helospectin-like peptides with VIP in all visualized nerve fibres and in some endocrine cells. It is concluded that PACAP-like and helospectin-like peptides coexist with VIP in nerves innervating the gut of two teleost species. The distribution suggests that both PACAP and helospectin, like VIP, are involved in the control of gut motility and secretion.     

Distribution and characterisation of immunoreactive somatostatin in human gastrointestinal tract

Immunoreactive somatostatin (IRS) was measured in acid extracts of human gastrointestinal tissue. The highest levels were found in the duodenum, pancreas, jejunum and stomach with lower levels in the ileum and colon. In the antrum, pylorus, duodenum and pancreas the main peak of IRS (1.6K IRS) coeluted with synthetic somatostatin-14 on both gel filtration chromatography and HPLC. In the body of stomach, jejunum, ileum and colon, a large peak coeluting with synthetic somatostatin-28 (3.5K IRS) on both chromatographic systems was also identified, while minor peaks of IRS assigned molecular weights of 6000 (6K) and greater than 15 000 (15K) were seen in some extracts. The total IRS content and pattern of molecular forms were similar in tissues obtained from adults at surgery or rapid post mortem, and in tissue taken from human fetuses after prostaglandin termination of pregnancy. When tissues were divided into mucosal and muscle layers, greater than 90% of the IRS was in the mucosa with less than 10% in the muscle layer. In the muscle layer the IRS was almost entirely the 1.6K form in all tissues. Immunohistochemical studies showed the IRS in the mucosa to be localised in endocrine-type cells, while in the muscle layer the IRS is present in nerve fibres and neurones of the myenteric plexus. It is suggested that (1) different mechanisms may control the biosynthesis of somatostatin-14 and somatostatin-28 in mucosal cells in different parts of the gut, (2) different biosynthetic controls may operate in endocrine-like and neuronal cells in the same region of the gut.     

胚胎小肠Cajal细胞的发育研究

目的研究人胚胎小肠cajal细胞的发育变化规律。方法采用全层铺片结合切片的免疫细胞化学技术。结果Cajal细胞呈酪氨酸激酶受体(Kit)和波形蛋白(vinlentin)免疫反应阳性。在胚胎发育早期,cajal细胞较少,为单层,稀疏分布于肌间神经丛周围,细胞为梭形,可见两个短而小的突起,未见分支;随着胎龄的增加,Cajal细胞数量增多,胞体增大,突起伸长,并出现分支。此时,肌间神经丛周围的Cajal细胞出现两层,其长轴彼此垂直,分别平行于环行肌和纵行肌。与此同时环行肌层内亦可见少许Cajal细胞;出生前,肌间神经丛部位的Cajal细胞接近成熟,两层细胞的突起进一步增多、伸长,彼此间形成与成人相似的完整的细胞网络。此时深肌丛附近亦可见少量Cajal细胞。结论人的小肠Cajal细胞发育有一定的时间顺序,即肌间神经丛周围最先出现,肌内次之,深肌丛较晚,出生前肌间神经丛周围的Cajal细胞已经接近成熟。这种发育演变若发生异常,可能导致某些胃肠动力障碍性疾病。     

Brain somatostatin receptors are up-regulated in somatostatin-deficient mice

The peptide somatostatin (SST) is widely synthesized in the brain and periphery and acts through a family of five receptors (SSTR1-5) to exert numerous effects. A gene product related to SST, cortistatin (CST), also interacts with SSTR1-5. Here we have investigated the regulation of SSTR1-5 and of CST in SST knockout (SSTKO) mice. The five SSTRs were quantitated individually by subtype-selective binding analysis, by immunocytochemistry, and by mRNA measurement and showed, in the brain of SSTKO mice, up-regulation of subtypes 1, 2, 4, and 5, and down-regulation of SSTR3. Peripheral tissues displayed both subtype- and tissue-specific changes in SSTR1-5 mRNA levels of expression. Lack of SST did not up-regulate normal CST expression in brain nor did it induce its expression in the periphery. SST-like immunoreactivity, however, was induced in the proximal midgut in SSTKO animals, suggesting intestinal expression of a novel SST-like gene.     

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways

Neuroendocrine tumours (NETs) may occur at many sites in the body although the majority occur within the gastroenteropancreatic axis. Non-gastroenteropancreatic NETs encompass phaeochromocytomas and paragangliomas, medullary thyroid carcinoma, anterior pituitary tumour, broncho-pulmonary NETs and parathyroid tumours. Like most endocrine tumours, NETs also express somatostatin (SST) receptors (subtypes 1–5) whose ligand SST is known to inhibit endocrine and exocrine secretions and have anti-tumour effects. In the light of this knowledge, the idea of using SST analogues in the treatment of NETs has become increasingly popular and new studies have centred upon the development of new SST analogues. We attempt to review SST receptor (SSTR) biology primarily in neuroendocrine tissues, focusing on pituitary tumours. A full data search was performed through PubMed over the years 2000–2009 with keywords ‘somatostatin, molecular biology, somatostatin receptors, somatostatin signalling, NET, pituitary’ and all relevant publications have been included, together with selected publications prior to that date. SSTR signalling in non-neuroendocrine solid tumours is beyond the scope of this review. SST is a potent anti-proliferative and anti-secretory agent for some NETs. The successful therapeutic use of SST analogues in the treatment of these tumours depends on a thorough understanding of the diverse effects of SSTR subtypes in different tissues and cell types. Further studies will focus on critical points of SSTR biology such as homo- and heterodimerization of SSTRs and the differences between post-receptor signalling pathways of SSTR subtypes.     

VIP-, substance P-, gastrin/CCK-, bombesin-, somatostatin- and glucagon-like immunoreactivities in the gut of the rainbow trout,Salmo gairdneri

Summary The presence of peptides in the gastrointestinal tract of the rainbow trout, Salmo gairdneri, was investigated immunocytochemically. VIP-like immunoreactivity was demonstrated in nerves in all layers of the stomach and the intestine, whereas substance P-like immunoreactivity was localized to endocrine cells, predominantly in the mucosa of the stomach, and to nerves mainly concentrated in the myenteric plexus throughout the gut. Endocrine cells reactive to gastrin/CCK antiserum were demonstrated in the intestinal mucosa, while no immunoreactivity was found in the stomach. Bombesin-immunoreactive and somatostatin-immunoreactive cells were localized in the stomach mucosa, and cells reactive to glucagon antiserum in the intestinal mucosa. Radioimmunoassay of stomach mucosa and muscle confirmed the presence of VIP-like and substance P-like immunoreactivity in these tissues, while gastrin/CCK-like immunoreactivity was low and bombesin-like immuno-reactivity was insignificant. In conclusion, molecules resembling the mammalian brain-gut peptides may be involved in the neuronal and hormonal control of gut function in fish.     

Cloning and expression of a novel mouse somatostatin receptor (SSTR2B).

A mouse somatostatin (SS) receptor cDNA was cloned from neuroblastoma x glioma (NG108-15) cells. The sequence is almost identical to that of the mouse SSTR2 receptor [(1992) Proc. Natl. Acad. Sci. USA 89, 251)] but lacks about 300 nucleotides between transmembrane domain VII and the C-terminus. This spliced variant of SSTR2 (designated SSTR2B) encodes a protein which is 23 residues shorter than that predicted from the SSTR2 sequence, and differs in 15 amino acids at the C-terminus. mRNA corresponding to SSTR2B occurs in mouse tissues in higher abundance than that of SSTR2. SSTR2B binds SS peptides with high affinity when expressed in mammalian cells.     

Hepatic clearance of somatostatin and gastrin-releasing peptide

In order to examine hepatic clearance of gastrointestinal regulatory peptides, rat livers were perfused in situ, and radiolabelled somatostatin (S-14, S-28), gastrin-releasing peptide (GRP-14, GRP-27), and vasoactive intestinal peptide (VIP) were injected into the portal vein and hepatic venous effluent was collected. S-14 and S-28 were not affected significantly by hepatic transit: 91.6 +/- 2.8% (SEM) of S-14 and 95.9 +/- 2.2% of S-28 were recovered, and neither peptide was degraded by hepatic transit, as determined by immunoprecipitation and gel chromatography. GRP-14 and GRP-27 were also not affected by hepatic transit: 91.5 +/- 1.6% of GRP-14 and 94.4 +/- 2.4% of GRP-27 were recovered intact. In contrast, when radiolabelled VIP was infused into the portal vein, 56.7 +/- 7.4% of injected labelled VIP appeared in the hepatic venous effluent, of which only 33.5 +/- 1.2% was intact peptide. Results of these studies indicate that enteric VIP released into the splanchnic/portal circulation is cleared by hepatic transit. However, somatostatin and GRP peptides appear to traverse the liver intact and could potentially produce systemic biological effects.